Central control of bone remodeling.
The hormonal control of osteoblast activity has been speculated for a long time. In search of such a central hormone, leptin was identified as an inhibitor of bone formation. Intracerebroventricular infusion of leptin resulted in a decrease of bone mass establishing that bone mass is regulated centrally. The peripheral mediator of leptin's action was identified as being the sympathetic nervous system. Mice deficient for catecholamines have high bone mass. beta-Receptor agonists decreased bone mass, and conversely, treatment by beta-blockers increased bone mass.
Takeda
Shu
S
Department of Orthopedics, 21st Century Center of Excellence (COE) Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. shu-tky@umin.ac.jp
D000818:Animals; D016723:Bone Remodeling / Q000502:physiology*; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism*; D020738:Leptin / Q000378:metabolism*; D051379:Mice; D009474:Neurons / Q000378:metabolism*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D013564:Sympathetic Nervous System / Q000378:metabolism*
D020738:Leptin; D011943:Receptors, Adrenergic, beta